Lycia Therapeutics Stock

www.lyciatx.comHealthcare / BioTech & PharmaFounded: 2019

Lycia Therapeutics is a biotechnology company and the developer of a treatment technology, Lysosomal Targeting Chimera (LYTAC), intended to degrade extracellular proteins with the goal of treating conditions including cancer, inflammation, and autoimmune disorders. Lycia Therapeutics was founded in 2019 by Dr. Carolyn Bertozzi and is headquartered in San Francisco, CA. The company is striving to uncover use cases for the LYTAC platform using extracellular protein degradation designed to target soluble and membrane-bound proteins.

Register To Buy and Sell Shares

For more details on financing and valuation for Lycia Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Lycia Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Lycia Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Aetna Wun Trombley Ph.D
President & Chief Executive Officer
Steve Staben Ph.D
Chief Scientific Officer
Sofia Touami Ph.D
Chief Business Officer
Jian Cao Ph.D
Vice President of Chemistry, Manufacturing and Controls (CMC)
Winsome Chung
Vice President of Finance
Matthew Holdren Ph.D
Vice President, Head of Nonclinical Development
Darrin Lindhout Ph.D
Executive Director, Head of Biologics
Sarah McWhirter Ph.D
Vice President, Head of Biology
Larry Rozsnyai Ph.D
Vice President of Intellectual Property
Nadia Tchao MD
Executive Director, Head of Translational Medicine/Early Development

Board Members

Andrew Gottesdiener MD
Venrock
Clare Ozawa Ph.D
Versant Ventures
Ming Fang
Redmile Group
Thomas Woiwode Ph.D
Versant Ventures
Timothy Anderson
Cowen Healthcare Investments

Frequently Asked Questions About Lycia Therapeutics’ Stock

plusminus
Can you buy Lycia Therapeutics’ stock?
Lycia Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Lycia Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Lycia Therapeutics’ stock?
Yes, you can sell stock of a private company like Lycia Therapeutics. Forge can help you sell your Lycia Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Lycia Therapeutics’ stock price?
Lycia Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Lycia Therapeutics’ private market stock price with Forge Data.
plusminus
What is Lycia Therapeutics’ stock ticker symbol?
Lycia Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Lycia Therapeutics Lands $106M for Protein Degraders That Treat Autoimmune & Inflammatory Diseases
In a series C funding round led by Venrock Healthcare Capital Partners, Lycia Therapeutics raised $106 million.
Updated on: May 25, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.